Precigen, Inc.
NASDAQ:PGENBiotechnology
-$0.10 today
- Market cap
- $1.53B
- Beta
- 1.06
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.65
Volume 4.27M
Average 4.72M
PGEN Total Current Liabilities
All obligations due within one year.
Precigen, Inc.NASDAQ: PGEN
Total Current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total current liabilities rises 26.6% from a year ago
Total current liabilities stood at $29.35M at the end of Q2 FY2026, up 26.6% from a year earlier and up 39.1% from the prior quarter. Over 3 fiscal years it compounded at -22.0% a year.
Context
- Total current liabilities amounted to 17.2% of total assets at the end of Q2 FY2026, down 5.5 pp from a year earlier.
- Total current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +26.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 37.31M USD
- Year-over-year change
- +73.4%
- 4-year CAGR
- +1.9%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 37.31M | +73.4% |
| FY2024 | 2024-12-31 | 21.52M | -6.4% |
| FY2023 | 2023-12-31 | 22.99M | -70.8% |
| FY2022 | 2022-12-31 | 78.65M | +127.0% |
| FY2021 | 2021-12-31 | 34.65M | — |
Total Current Liabilities vs competitors
How PGEN compares with its peers on the latest reported figures
- PGEN's Jun 2026 total current liabilities of $29.35M is the 6th highest of the 8 companies compared; the peer median is $39.78M.
- Its year-over-year change of +26.6% is the 2nd highest of 8, against a peer median of -32.1%.
- Total current liabilities amounts to 17.2% of total assets for PGEN, versus a peer median of 10.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $140.96M | +18.5% | +7.2% | 5.5% | |
| Mar 2026 | $76.45M | -32.1% | -6.4% | 10.1% | |
| Mar 2026 | $71.11M | -33.4% | -3.3% | 20.8% | |
| Mar 2026 | $39.78M | -45.6% | -8.4% | 26.6% | |
| Mar 2026 | $31.05M | +72.6% | +56.1% | 15.6% | |
| Jun 2026 | $29.35M | +26.6% | -22.0% | 17.2% | |
| Mar 2026 | $24.47M | -30.7% | -8.3% | 8.6% | |
| Mar 2026 | $7.76M | -37.4% | -46.9% | 5.4% | |
| Peer median (excluding PGEN) | $39.78M | -32.1% | -6.4% | 10.1% | |
Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 36.42M | 4.86M | 7.58M | 29.52M | 30.23M |
| Short-term Investments | 72.24M | 51.09M | 55.28M | 68.39M | 67.62M |
| Net Receivables | 1.98M | 13.8M | 1.58M | 1.16M | 4.36M |
| Inventory | 326K | 287K | 0 | 0 | 9.58M |
| Other Current Assets | 38.92M | 48.12M | 4.33M | 3.34M | 3.43M |
| Total Current Assets | 156.63M | 118.16M | 68.76M | 102.41M | 115.24M |
| Property, Plant & Equipment (Net) | 18.55M | 15.29M | 14.13M | 18.8M | 18.44M |
| Goodwill | 37.55M | 36.92M | 26.61M | 19.14M | 15.23M |
| Intangible Assets | 52.29M | 44.46M | 40.7M | 4.46M | 3.18M |
| Long-term Investments | 48.56M | 399K | 0 | 0 | 2.51M |
| Tax Assets | 0 | 9.17M | 0 | 0 | 1.12M |
| Other Non-current Assets | 46.27M | (8.42M) | 846K | 459K | 908K |
| Total Non-current Assets | 203.23M | 97.82M | 82.29M | 42.85M | 41.39M |
| Total Assets | 359.86M | 215.98M | 151.04M | 145.27M | 156.62M |
| Account Payables | 3.11M | 4.07M | 1.73M | 3.53M | 11.99M |
| Short-term Debt | 52K | 43.22M | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 1.49M | 25K | 509K | 589K | 517K |
| Other Current Liabilities | 20.71M | 23.75M | 8.25M | 8.42M | 10.2M |
| Total Current Liabilities | 34.65M | 78.65M | 22.99M | 21.52M | 37.31M |
| Long-term Debt | 179.88M | 0 | 0 | 0 | 93.17M |
| Deferred Tax Liabilities | 2.54M | 2.26M | 1.85M | 0 | 1.12M |
| Deferred Revenue (Non-current) | 23.02M | 1.82M | 1.82M | 1.93M | 0 |
| Other Non-current Liabilities | 3.67M | 0 | 0 | 78.76M | 134K |
| Total Non-current Liabilities | 217.86M | 11.07M | 9.56M | 85.24M | 98.4M |
| Total Liabilities | 252.51M | 89.72M | 32.55M | 106.75M | 135.71M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (1.92B) | (1.87B) | (1.96B) | (2.09B) | (2.34B) |
| Accumulated OCI | 203K | (3.49M) | (1.95M) | 12K | 7K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 107.35M | 126.26M | 118.5M | 38.51M | 20.91M |
| Total Debt | 190.07M | 51.42M | 7.1M | 5.5M | 98.29M |
| Net Debt | 153.65M | 46.56M | (481K) | (24.02M) | 68.06M |
Precigen, Inc.
NASDAQ:PGEN
Intrinsic Alpha fair value
Locked
Current Price
$4.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.